Ruxolitinib

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Severe/Very Severe COVID-19 Illness

Conditions

Severe/Very Severe COVID-19 Illness

Trial Timeline

— → —

NCT ID

NCT04337359

About Ruxolitinib

Ruxolitinib is a pre-clinical stage product being developed by Novartis for Severe/Very Severe COVID-19 Illness. The current trial status is completed. This product is registered under clinical trial identifier NCT04337359. Target conditions include Severe/Very Severe COVID-19 Illness.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05269771	Pre-clinical	Completed	—	—	Polycythemia Vera
NCT04745637	Pre-clinical	Active	—	—	Primary Myelofibrosis (PMF)
NCT04337359	Pre-clinical	Completed	—	—	Severe/Very Severe COVID-19 Illness
NCT06824103	Approved	Recruiting	Sep 9, 2025	Jan 11, 2032	Graft vs. Host Disease
NCT06462469	Approved	Recruiting	Jul 4, 2024	Feb 17, 2028	Steroid-refractory Acute Graft Versus Host Disease
NCT03491215	Phase 1/2	Completed	Feb 21, 2019	Feb 2, 2023	Acute Graft Versus Host Disease
NCT02966353	Phase 2	Completed	Mar 31, 2017	Feb 15, 2019	Primary Myelofibrosis
NCT02292446	Phase 3	Completed	Nov 21, 2014	Dec 29, 2017	Polycythemia Vera
NCT02091752	Phase 2	Terminated	Sep 1, 2014	Feb 1, 2015	Primary Myelofibrosis
NCT02049450	Phase 2	Completed	May 28, 2014	Apr 12, 2016	Thalassemia Major
NCT02072057	Phase 2	Terminated	Apr 20, 2014	Nov 30, 2018	Cancer Cachexia
NCT02015208	Phase 1/2	Completed	Apr 1, 2014	Jul 1, 2015	Chronic Lymphocytic Leukemia
NCT02087059	Phase 3	Completed	Apr 1, 2014	Apr 1, 2015	Primary Myelofibrosis (MF)
NCT01877005	Phase 2	Completed	Jul 4, 2013	Jun 12, 2018	Hodgkin's Lymphoma
NCT01317875	Phase 1	Completed	Mar 31, 2011	Dec 31, 2019	Myelofibrosis
NCT01392443	Phase 2	Completed	Oct 14, 2010	Oct 31, 2017	Primary Myelofibrosis (MF)